Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2–5 Years of Age Homozygous for F508del-CFTR : A Phase 2, Open-Label Clinical Trial
- 1 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 21 (11) , 1550-1559
Abstract
Rationale: Clinical trials show that lumacaftor/ivacaftor (LUM/IVA) treatment has the potential to modify early cystic fibrosis (CF) disease progression in children as young as 2 years of age. Objectives: To assess the long-term impact of LUM/IVA treatment on CF disease progression in children aged 2–5 years. Methods: This phase 2 trial had two parts: part 1, a 48-week, randomized, double-blind, placebo-controlled study of LUM/IVA in children aged 2–5 years (previously reported) was followed by a 48-week open-label treatment period in which all children received LUM/IVA (part 2; reported here). Endpoints assessed in part 2 included absolute changes from baseline in chest magnetic resonance imaging (MRI) global score at Week 96; weight-for-age, stature-for-age, and body mass index (BMI)-for-age z-scores at Week 96; lung clearance index based on lung volume turnover required to reach 2.5% of starting N2 concentration (LCI2.5) through Week 96; chest MRI morphological score, chest MRI perfusion score, weight, stature, BMI, and microbiology cultures (oropharyngeal swabs) at Week 96; sweat chloride, amount of immunoreactive trypsinogen, fecal elastase-1 concentration, and fecal calprotectin through Week 96; and number of pulmonary exacerbations, time to first pulmonary exacerbation, and number of CF-related hospitalizations. Results: Forty-nine children received one or more doses of LUM/IVA in the open-label period (33 in the LUM/IVA to LUM/IVA group and 16 in the placebo to LUM/IVA group), with a mean exposure of 47.1 (standard deviation [SD], 5.2) weeks. The mean absolute change in MRI global score (negative value indicates improvement) from baseline at Week 96 was −2.7 (SD, 7.0; 95% confidence interval [CI], −5.2 to −0.1) in the LUM/IVA to LUM/IVA group and −5.6 (SD, 6.9; 95% CI, −9.2 to −1.9) in the placebo to LUM/IVA group. Improvements in LCI2.5, sweat chloride concentration, and markers of pancreatic function and intestinal inflammation were also observed in both groups. Growth parameters remained stable in both groups. The majority of children had adverse events considered mild (38.8%) or moderate (40.8%). Two (4.1%) children discontinued LUM/IVA treatment because of adverse events (distal intestinal obstruction syndrome [n = 1] and alanine aminotransferase increase [n = 1]). Conclusions: These findings confirm the potential for early LUM/IVA treatment to alter the trajectory of CF disease progression, including CF lung disease, in children as young as 2 years of age. Clinical trial registered with ClinicalTrials.gov (NCT03625466).Keywords
This publication has 41 references indexed in Scilit:
- Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosisJournal of Cystic Fibrosis, 2022
- Worldwide rates of diagnosis and effective treatment for cystic fibrosisJournal of Cystic Fibrosis, 2022
- Novel imaging techniques for cystic fibrosis lung diseasePediatric Pulmonology, 2021
- The Clinical Use of Lung MRI in Cystic FibrosisChest, 2020
- Sensitive structural and functional measurements and 1-year pulmonary outcomes in pediatric cystic fibrosisJournal of Cystic Fibrosis, 2020
- Pancreatic insufficiency in Cystic FibrosisJournal of Cystic Fibrosis, 2017
- Early detection and sensitive monitoring of CF lung disease: Prospects of improved and safer imagingPediatric Pulmonology, 2016
- Impact of different breathing protocols on multiple-breath washout outcomes in childrenJournal of Cystic Fibrosis, 2014
- Morphologic and functional scoring of cystic fibrosis lung disease using MRIEuropean Journal of Radiology, 2012
- Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic-sufficient patients with cystic fibrosisThe Journal of Pediatrics, 1995